字号·· | 护眼
美国广播公司

研究显示GLP-1类药物或对年仅6岁儿童有效,孩子该用吗?Study shows GLP-1s may work in children as young as 6. Should kids be using them?

点「原文对照」整页切到原文,或双击某段只看那段的原文。

2024年4月24日,芝加哥一家药房的柜台上摆放着数盒减肥药物Wegovy。Scott Olson/Getty ImagesBoxes of weight-loss medication Wegovy are seen on a counter at a pharmacy in Chicago, April 24, 2024. Scott Olson/Getty Images

发布时间:2026-11-18T19:48:05Z 最新研究显示,一种常见的减重药物可能对年仅6岁的肥胖儿童有效。

Published: 2026-11-18T19:48:05Z New research shows a common weight loss medication may be effective in treating obesity in children as young as 6 years old.

诺和诺德本周在一场肥胖医学会议上分享了其药物Wegovy(司美格鲁肽注射液)的一项3期临床试验结果,显示该药使大多数6至11岁肥胖儿童的体重指数(BMI)降低了10%或更多。

Novo Nordisk shared results from a phase 3 clinical trial at an obesity medicine conference this week showing that its drug, Wegovy, reduced Body Mass Index by 10% or more among most children with obesity ages 6 through 11.

经过68周,服用司美格鲁肽(Wegovy的活性成分)的儿童中,近40%不再患有肥胖。相比之下,服用安慰剂的患者几乎全部在该时期结束时仍患有肥胖。

After 68 weeks, almost 40% of children taking semaglutide -- the active ingredient in Wegovy -- no longer had obesity. By comparison, nearly all the patients taking the placebo still had obesity after that period.

对于2至19岁的儿童和青少年,肥胖传统上被定义为体重指数达到30或更高。

For children and adolescents ages 2 to 19, is traditionally defined as having a body mass index of 30 or higher.

Weygovy目前已获美国食品药品监督管理局(FDA)批准用于12岁及以上儿童,但诺和诺德表示计划向该机构申请降低适用年龄。

Wegovy is currently approved by the Food and Drug Administration for children as young as 12 years old, but Novo Nordisk says it plans to file with the agency to lower the age.

世界卫生组织目前建议10岁以下儿童不应接受药物减重治疗,而应侧重于饮食和运动。

The World Health Organization currently recommends against children under 10 years old receiving pharmacological weight-loss treatments and to instead focus on diet and exercise.

医生们一致认为,肥胖是一个需要解决的公共和个人健康问题;美国疾病控制与预防中心(CDC)称,美国约有五分之一的儿童和青少年患有肥胖。然而,医生们对于GLP-1类药物在年幼儿童中应推广到何种程度,反应不一。

Physicians agree that obesity is a public and personal health concern that needs to be addressed; the Centers for Disease Control and Prevention says approximately one in five U.S. children and adolescents have obesity. However, there is mixed reaction among doctors regarding how widely GLP-1s should be used in younger children.

未参与该试验的纽约大学朗格尼医学中心哈森费尔德儿童医院儿科内分泌与糖尿病科主任玛丽·帕特·加拉格尔医生称这些发现为“非凡的结果”。一些医生表示,通过给年幼儿童开具这些药物来应对肥胖,有助于预防孩子发展为重度肥胖或相关疾病,包括脂肪肝和睡眠呼吸暂停。

Dr. Mary Pat Gallagher, director of the division of pediatric endocrinology and diabetes at Hassenfeld Children's Hospital at NYU Langone, who was not involved in the trial, referred to the findings as "a remarkable result." Some doctors say that addressing obesity in young children by prescribing these medications can help prevent kids from developing severe obesity or related conditions, including fatty liver disease and sleep apnea.

Gallagher 告诉 ABC 新闻,一些儿童已经患有这些疾病,使用 GLP-1 类药物可能是治疗肥胖症更有效的方法,有可能减少未来因这些并发症而不得不服用多种药物的情况。

Gallagher told ABC News some children already have those conditions and using GLP-1s could be a more effective treatment for obesity potentially reducing having to take several medications for these complications in the future.

Gallagher 说:“与其服用降压药和治疗脂肪肝的药物,或者晚上戴着 CPAP 或 BiPAP 呼吸机治疗阻塞性睡眠呼吸暂停,通过治疗肥胖症,你可能只需一种药物就能治疗所有这些问题。”

"Instead of taking a blood pressure medication and some drug to treat fat in your liver or wearing a CPAP or a BiPAP at night for your obstructive sleep apnea, by treating obesity, you could be treating all of those with just one medication," Gallagher said.

同样未参与该试验的、在儿科和预防医学方面拥有专科认证的医生 Jade Cobern 表示,GLP-1 类药物在年轻人群中有效并不令人惊讶,但有一些因素需要考虑,例如副作用。

Dr. Jade Cobern, board certified in pediatrics and preventive medicine, who was also not involved in the trial, said it's not surprising that GLP-1s are effective in a younger population, but there are some things to consider, such as side effects.

Cobern 表示,诺和诺德的研究发现没有新的重大安全顾虑,但胃肠道副作用在司美格鲁肽组更为常见。司美格鲁肽组 70% 的参与者出现呕吐,而安慰剂组为 29%。

The Novo Nordisk study found there were no new major safety concerns, but gastrointestinal side effects were more common in the semaglutide group. Vomiting occurred in 70% of the participants in the semaglutide group compared to 29% of those in the placebo group, Cobern said.

她补充说,此外,司美格鲁肽组 62% 的参与者出现腹泻,安慰剂组为 35%;司美格鲁肽组 58% 出现恶心,安慰剂组为 24%。

Additionally, diarrhea occurred in 62% of the semaglutide group versus 35% of the placebo group and nausea in 58% and 24%, respectively, she added.

Cobern 告诉 ABC 新闻:“当我们谈论研究中司美格鲁肽组 70% 的孩子出现呕吐时,这对一个 6 岁孩子意味着什么,以及这种程度的呕吐对 6 岁孩子的影响,与对 19 岁或 30 岁年轻人的影响截然不同。这会如何影响他们日常生活、留在学校上学、在上学日进行学习的能力?这些都是我们必须密切关注的非常重要的问题。” 司美格鲁肽组儿童的线性生长——即身长或身高的增长——与安慰剂组相比也存在差异。

"When we talk about 70% of the kids in the semaglutide group in the study who experience vomiting, what that looks like for a 6-year-old, and the degree of how that can impact a 6-year-old is very different than how that might impact a 19-year-old or a 30-year-old," Cobern told ABC News. "How does that vomiting impact their ability to go about their day, their ability to stay in school, their ability to learn throughout the school day? These are really important questions that we are going to have to watch very closely." There was also a difference in linear growth -- meaning the increase in length or height -- among children in the semaglutide group compared to the placebo group.

试验发现,服用司美格鲁肽的儿童比未服药儿童少长约 1.3 英寸(约 3.3 厘米)。

The trial found children on semaglutide grew about 1.3 inches less than those who did not take the drug.

科伯恩表示,还需要更多后续研究来了解这些药物可能如何影响儿童的生长发育和身体构成,而这两点在儿童成长过程中都很重要。

Cobern said more follow-ups are needed to understand how these drugs could impact a child's growth and body composition, both of which are important as children age.

2026年11月3日,丹麦巴格斯韦德,制药公司诺和的标志展示在其办公楼前。Tom Little/路透社The logo of pharmaceutical company Novo is displayed in front of its offices in Bagsvaerd, Denmark, November 3, 2026. Tom Little/Reuters

加拉格尔表示,在权衡获益与风险时,即便“有人可能因此损失半英寸身高”只是一种“理论上的可能性”,也不会阻止她给患有肥胖症、同时伴有阻塞性睡眠呼吸暂停或高血压等疾病的儿童开具GLP-1类药物。

Gallagher said when considering the benefits compared to the risks, the "theoretical possibility that someone might lose half an inch of height" would not prevent her from prescribing a GLP-1 to a child with obesity who has obstructive sleep apnea or high blood pressure, for example.

“我绝对不希望传递出的信息是,在获得更多信息之前我们不应该使用这些药物,”加拉格尔说。“我认为儿童肥胖确实是个现实问题。它是一种慢性疾病,我们确实需要采取行动。”科伯恩也认同,对于部分患有严重肥胖症的儿童,当饮食和生活方式干预效果不足时,这种药物可以成为一种潜在手段,但不应用作一线方案或单独使用的方案。

"I definitely don't want the message to be that we shouldn't use these medications [until] we have more information," Gallagher said. "I think we have a real problem with childhood obesity. It is a chronic illness and we do need to do something about it." Cobern agreed that the medication is a potential tool for some children with severe obesity when diet and lifestyle interventions are insufficient, just not as a first-line or standalone approach.

“我们确实从肥胖医学医生那里听说,他们在一些较年幼的年龄组中遇到了瓶颈,因此他们希望工具箱里有更多工具,而这种药物有可能成为其中之一,”她说。“但再次强调——它只是一个工具——不是唯一的工具,也不是唯一的重点。”

"We do hear from obesity medicine doctors that they hit a wall in some of these younger age groups, and so they have wanted more tools in the toolbox, which this potentially could be," she said. "But again -- a tool -- [and] not the only tool and not the only focus."

阅读媒体原文 ↗